Update on the use of direct oral anticoagulants for the prevention and treatment of thromboembolism

被引：0
|
作者：
Jacobs, Anna [1 ,2 ]
Kabra, Rajesh [3 ]
Das, Pranab [4 ]
Oliphant, Carrie S. [1 ,2 ]
机构：
[1] Methodist Univ Hosp, Dept Pharm, 1265 Union Ave, Memphis, TN 38104 USA
[2] Univ Tennessee, Coll Pharm, Dept Clin Pharm, 920 Madison Ave, Memphis, TN 38163 USA
[3] Univ Tennessee, Hlth Sci Ctr, Div Cardiol, 1325 Eastmoreland Ave Suite 460, Memphis, TN 38104 USA
[4] St Francis Cardiol Associates, 6005 Pk Ave,Suite500 B, Memphis, TN 38119 USA
来源：
FUTURE CARDIOLOGY | 2018年 / 14卷 / 01期
关键词：
apixaban; atrial fibrillation; betrixaban; dabigatran; edoxaban; review; rivaroxaban; venous thromboembolism;
D O I：
10.2217/fca-2017-0045
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Following publication of our review article 4 years ago, there has been an uptake in the use of nonvitamin K oral antagonists, also known as direct oral anticoagulants. The most recent Xa inhibitors to receive approval are edoxaban, which has been approved for use in both atrial fibrillation and venous thromboembolism prevention and betrixaban, which has been approved in the USA for extended thromboprophylaxis in the medically ill population. Additional analyses of certain types of atrial fibrillation patients have now become available. Ongoing prescriber vigilance is recommended as additional information continues to emerge with this class of medications. The purpose of this paper is to provide an update on the use of the direct oral anticoagulant agents for the prevention and treatment of thromboembolism.
引用
收藏
页码：89 / 99
页数：11
相关论文
共 50 条
  • [41] Retrospective, multicenter analysis of the safety and effectiveness of direct oral anticoagulants for the treatment of venous thromboembolism in obesity
    Sperry, Jeffrey D.
    Loeb, Aletha
    Smith, Melissa J.
    Brighton, Tessa B.
    Ehret, Julie A.
    Fermo, Joli D.
    Gentili, Morgan E.
    Lancaster, Jason W.
    Mazur, Jennifer N.
    Spezzano, Katherine
    Szwak, Jennifer A.
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2024, 57 (04) : 603 - 612
  • [42] Direct oral anticoagulants and cardiovascular prevention in patients with nonvalvular atrial fibrillation
    Marin, Francisco
    Anguita-Sanchez, Manuel
    Sanmartin, Marcelo
    EXPERT OPINION ON PHARMACOTHERAPY, 2017, 18 (01) : 67 - 77
  • [43] Efficacy and Safety of Direct Oral Anticoagulants for Risk of Cancer-Associated Venous Thromboembolism
    Zeng, Jie
    Zhang, Xuhui
    Lip, Gregory Y. H.
    Shu, Xiaochen
    Thabane, Lehana
    Tian, Junzhang
    Li, Guowei
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2019, 25
  • [44] Treatment of Venous Thromboembolism in Special Populations with Direct Oral Anticoagulants
    Bavalia, Roisin
    Middeldorp, Saskia
    Weisser, Gerhard
    Espinola-Klein, Christine
    THROMBOSIS AND HAEMOSTASIS, 2020, 120 (06) : 899 - 911
  • [45] New Anticoagulants for the Prevention of Thromboembolism
    Lepic, Kylie
    Crowther, Mark
    CURRENT PHARMACEUTICAL DESIGN, 2010, 16 (31) : 3472 - 3474
  • [46] New oral anticoagulants in the treatment of venous thromboembolism: Critical analysis of clinical trials
    Paramo, J. A.
    Alfonso, A.
    Lecumberri, R.
    ANGIOLOGIA, 2015, 67 (05): : 409 - 414
  • [47] An update on applications and limitations of direct oral anticoagulants
    Wei, Sharon
    Sawhney, Aanchal
    Khandait, Harshwardhan
    Meda, Amit
    Gupta, Vasu
    Jain, Rohit
    EGYPTIAN JOURNAL OF INTERNAL MEDICINE, 2023, 35 (01):
  • [48] Use of direct oral anticoagulants in daily practice
    Almarshad, Feras
    Alaklabi, Ali
    Bakhsh, Ebtisam
    Pathan, Aslam
    Almegren, Mosaad
    AMERICAN JOURNAL OF BLOOD RESEARCH, 2018, 8 (04): : 57 - 72
  • [49] Physician perceptions and use of reduced-dose direct oral anticoagulants for extended phase venous thromboembolism treatment
    Groat, Danielle
    Martin, Karlyn A.
    Rosovsky, Rachel P.
    Sanfilippo, Kristen M.
    Gaddh, Manila
    Kreuziger, Lisa Baumann
    Eyster, M. Elaine
    Woller, Scott C.
    RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2022, 6 (04)
  • [50] Clinical trials with new direct oral anticoagulants
    Harenberg, J.
    Weiss, C.
    Marx, S.
    Zolfaghari, S.
    PHLEBOLOGIE, 2013, 42 (03) : 139 - 148
12345